Friday, November 26, 2010
Genomma Lab Delivers Remarkable Top Line Growth of 122.4% and EBITDA Growth of 139.3% in 4Q09
MEXICO CITY -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the fourth quarter and full year periods ended December 31, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company’s Spanish operations reclassified as discontinued operations according to Mexican GAAP.
4Q09 Highlights (vs. 4Q08)
Net Sales for the quarter reached Ps. 1,666.4 million, an increase of 122.4%
EBITDA1 increased 139.3%, to Ps. 507.6 million. This represents a 30.5% margin during the fourth quarter.
Earnings per Share2 increased 49.0%, to Ps. 1.44.
International Net Sales rose 84.7%, to Ps. 190.8 million.
During the fourth quarter, Genomma Lab successfully launched 11 products under 6 existing brands (Base Brands3 and Prior Year Launches4) as part of its line extension strategy.
Full Year 09 Highlights (vs. 08)
Net Sales reached Ps. 4,424.7 million, an increase of 68.3%.
EBITDA5 increased 65.5%, to Ps. 1,143.6 million. This represents a 25.8% margin during the period.
Earnings per Share6 increased 34.6% to Ps. 1.44 during 2009.
International Net Sales rose 183.0%, to Ps. 618.4 million.
Consolidated Net Income increased 48.2% to Ps. 760.0 million.
During 2009, Genomma Lab successfully launched 25 products under 15 existing brands (Base Brands7 and Prior Year Launches8) as part of its line extension strategy.
The Company also launched 216 products under 13 New Brands9, as part of its new product launch plan during the year.
Medicamentos | Caida del Cabello | Optica | Cicatrices | Bajar de Peso | Cremas